{
  "id": "5be48c39133db5eb7800001d",
  "type": "factoid",
  "question": "What does the pembrolizumab companion diagnostic test assess?",
  "ideal_answer": "Administration of pembrolizumab requires a companion diagnostic test, to assess PD-L1 status of patients.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/28293123"
  ],
  "snippets": [
    {
      "text": "The initial approval and subsequent studies of pembrolizumab required and utilized a companion diagnostic test, Dako's IHC 22C3, to assess PD-L1 status of patients.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28293123",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "PD-L1 status"
}